West Pharmaceutical Services Inc

WST remains in a Stage 2 advancing regime with clear higher highs and higher lows supported by rising EMAs. Price is currently extended above its dynamic support and overbought, so patience is warranted. A pullback into the rising 9-EMA and 20-EMA zone would offer a structurally favorable entry.

• ↑Q1 revenue up 21% YoY to $845 M; adj. EPS rose 47% to $2.13
• ↑Full-year organic revenue growth outlook raised to 7%–9%; EPS guidance at $8.40–$8.75
• ↓Current valuation appears expensive, reflecting high growth expectations